K Pharma,Inc. (4896.T)
JPY 854.0
(-5.01%)
JPY 854.0
(-5.01%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 366.05 Million JPY | 203.47% |
| 2022 | -353.77 Million JPY | -61.18% |
| 2021 | -219.49 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -192.7 Million JPY | 16.5% |
| 2024 Q1 | -230.78 Million JPY | -54.08% |
| 2023 Q3 | -135.27 Million JPY | 0.0% |
| 2023 Q4 | -149.77 Million JPY | -10.72% |
| 2023 FY | 366.05 Million JPY | 203.47% |
| 2022 FY | -353.77 Million JPY | -61.18% |
| 2021 FY | -219.49 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 38.666% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | 173.673% |
| GNI Group Ltd. | 13.1 Billion JPY | 97.208% |
| Linical Co., Ltd. | 725.72 Million JPY | 49.56% |
| Trans Genic Inc. | 89.43 Million JPY | -309.295% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 125.671% |
| Soiken Holdings Inc. | -610 Million JPY | 160.009% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | 147.371% |
| AnGes, Inc. | -11.96 Billion JPY | 103.059% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 132.66% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 103.843% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | -250.969% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | 142.347% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 132.772% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 129.006% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | 145.84% |
| RaQualia Pharma Inc. | -337.36 Million JPY | 208.505% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 130.374% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 127.408% |
| PeptiDream Inc. | 6.77 Billion JPY | 94.595% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 118.967% |
| Ribomic Inc. | -1.11 Billion JPY | 132.795% |
| SanBio Company Limited | -4.53 Billion JPY | 108.065% |
| Healios K.K. | -3.37 Billion JPY | 110.833% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 131.691% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 126.269% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 126.091% |
| StemRIM | -2.07 Billion JPY | 117.633% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 70.032% |
| FunPep Company Limited | -994 Million JPY | 136.827% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 141.187% |
| Stella Pharma Corporation | -760.3 Million JPY | 148.146% |
| TMS Co., Ltd. | -943.25 Million JPY | 138.808% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 147.209% |
| Cuorips Inc. | -588.48 Million JPY | 162.203% |
| Takara Bio Inc. | 3 Billion JPY | 87.81% |
| ReproCELL Incorporated | -409.29 Million JPY | 189.436% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | -3208.84% |
| StemCell Institute Inc. | 413.75 Million JPY | 11.529% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | -153.314% |
| CellSeed Inc. | -697.77 Million JPY | 152.461% |